FDA Grants Accelerated Approval to Bristol-Myers Squibb’s Augtyro for Treatment of NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Augtyro’s approval was based on results from the Phase I/II TRIDENT-1 trial, which showed significant response rates in both tyrosine kinase inhibitor (TKI)-naïve and TKI-experienced patients.